Diagnostic Accuracy of 3T MR for Secondary Hyperparathyroidism Comparison With 4DCT
NCT ID: NCT05540795
Last Updated: 2023-09-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
15 participants
OBSERVATIONAL
2023-02-06
2023-07-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prevalence of Secondary Hyperparathyroidism Among Patients With Diabetic Nephropathy
NCT03137316
Preemptive and Precise Intervention for CKD-SHPT
NCT04523974
Thermal Ablation Versus Parathyroidectomy for Secondary Hyperparathyroidism
NCT06709586
The Relation Between Thyroid , Parathyroid Hormones and eGFR in CKD Patients in Assiut
NCT05243979
IOPTH Usefulness for Predicting Successful Surgery in Secondary Hyperparathyroidism
NCT04484116
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
4DCT images were scanned with the 128-section dual-source multi-detector row unit (Somatom Definition Flash; Siemens Medical Solutions). All patients were scanned from the angle of the mandible to the carina. The 4DCT protocol included the acquisition of unenhanced images followed by the acquisition of arterial and delayed (venous) phase image series. Unenhanced images were obtained by using the following parameters: a collimation of 64×0.6 mm, 120 kVp for the deliverance of a dose-modulated amperage of 250 mAs, a pitch of 0.7, and a gantry rotation time of 0.28 seconds. The arterial and venous phase scans was performed in dual-energy mode with a dual source of 80 kVp and 140 kVp tube voltages using the following parameters: tube current-time product 230 and 89 mAs, respectively; collimation, 64 × 0.6 mm; rotation speed, 0.28 seconds; and helical pitch, 0.7. The arterial and venous phase scanning began automatically at 10 s and 35 s after the left common carotid artery reached the trigger attenuation threshold (100 HU) using automated scan-triggering software (CARE Bolus CT; Siemens Healthineers). The volume of iodinated contrast material (iohexol, Omnipaque 300; GE Healthcare, SH, China) was 70 mL, and the injection rate was 3 mL/s. The mean dual-source CT dose index volume was 34.5 mGy.
The sensitivity and specificity as well as the positive-predictive and negative-predictive values (PPV, NPV) of each imaging modality for preoperative parathyroid hyperplasia localization to the correct quadrant were compared. For the per-quadrant localization, if a lesion was suspected to be parathyroid hyperplasia by the imaging report and was correlated with the surgical and pathology results, this was interpreted as a true-positive lesion. Otherwise, if the lesion was not confirmed to be parathyroid hyperplasia during surgery, this was considered to be a false-positive case. If a lesion was not reported by the radiologist in the exact quadrant but was present during surgery and histopathologic examination, this was regarded as a false-negative lesion.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
RETROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
16 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fifth Affiliated Hospital, Sun Yat-Sen University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ying Wang
Director
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ying Wang, MD
Role: PRINCIPAL_INVESTIGATOR
Fifth Affiliated Hospital, Sun Yat-Sen University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
FifthSunYetSen
Zhuhai, Guangzhou, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ZDWY.HYXK.006
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.